A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS)

This article has no abstract
Epistemonikos ID: 31db6537c13d16bef66b6a811ddeadf9cd2a56ce
First added on: Feb 15, 2025